Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020112669 - IL-2 DEPENDENT NK-92 CELLS WITH STABLE FC RECEPTOR EXPRESSION

Publication Number WO/2020/112669
Publication Date 04.06.2020
International Application No. PCT/US2019/063069
International Filing Date 25.11.2019
IPC
A61K 35/17 2015.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
C07K 14/735 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
735Fc receptors
C12N 5/0783 2010.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07Animal cells or tissues
071Vertebrate cells or tissues, e.g. human cells or tissues
078Cells from blood or from the immune system
0783T cells; NK cells; Progenitors of T or NK cells
CPC
A61K 35/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07K 14/70535
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
70503Immunoglobulin superfamily
70535Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
C07K 16/2887
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
2887against CD20
C07K 16/32
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
32against translation products of oncogenes
C07K 2317/24
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
20characterized by taxonomic origin
24containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Applicants
  • NANTKWEST, INC. [US]/[US]
Inventors
  • NAVARRO, Francisco
  • KLINGEMANN, Hans G.
  • BOISSEL, Laurent H.
  • DANDAPAT, Abhijit
Agents
  • MAO, Yifan
  • SERAFINI, Andrew T.
  • THOMAS, Tiffany B.
  • BORING, Landin F.
  • LOCKYER, Jean M.
Priority Data
62/771,47926.11.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) IL-2 DEPENDENT NK-92 CELLS WITH STABLE FC RECEPTOR EXPRESSION
(FR) CELLULES NK-92 DÉPENDANTES DE L'IL-2 AYANT UNE EXPRESSION DE RÉCEPTEUR FC STABLE
Abstract
(EN)
Provided herein are populations of IL2 Dependent haNK® cells, which express a high affinity CD16 but does not express IL-2. These cells maintain stable expression of Fc receptor CD16 while retaining cytotoxicity. In some embodiments, the expression level of CD16 decreases no more than 20% when the cells are activated as compared to expression level of CD16 on the cells before activation. Compositions and kits comprising the cells, and methods of making and using the IL2 Dependent haNK® cells are also provided.
(FR)
L'invention concerne des populations de cellules haNK® dépendantes de l'IL-2, qui expriment un CD16 à haute affinité mais n'expriment pas l'IL-2. Ces cellules maintiennent une expression stable du récepteur Fc CD16 tout en conservant une cytotoxicité. Dans certains modes de réalisation, le niveau d'expression du CD16 ne diminue pas de plus de 20 % lorsque les cellules sont activées par comparaison avec le niveau d'expression du CD16 sur les cellules avant activation. L'invention concerne également des compositions et des kits comprenant les cellules, et des méthodes de fabrication et d'utilisation des cellules haNK® dépendantes de l'IL-2.
Latest bibliographic data on file with the International Bureau